Literature DB >> 29764917

The path to VICTORy - a beginner's guide to success using commercial research antibodies.

Simon L Goodman.   

Abstract

Commercial research antibodies are crucial tools in modern cell biology and biochemistry. In the USA some $2 billion a year are spent on them, but many are apparently not fit-for-purpose, and this may contribute to the 'reproducibility crisis' in biological sciences. Inadequate antibody validation and characterization, lack of user awareness, and occasional incompetence amongst suppliers have had immense scientific and personal costs. In this Opinion, I suggest some paths to make the use of these vital tools more successful. I have attempted to summarize and extend expert views from the literature to suggest that sustained routine efforts should made in: (1) the validation of antibodies, (2) their identification, (3) communication and controls, (4) the training of potential users, (5) the transparency of original equipment manufacturer (OEM) marketing agreements, and (5) in a more widespread use of recombinant antibodies (together denoted the 'VICTOR' approach).
© 2018. Published by The Company of Biologists Ltd.

Keywords:  Antibodies; Reproducibility crisis; VICTOR

Mesh:

Substances:

Year:  2018        PMID: 29764917     DOI: 10.1242/jcs.216416

Source DB:  PubMed          Journal:  J Cell Sci        ISSN: 0021-9533            Impact factor:   5.285


  4 in total

1.  A dataset describing a suite of novel antibody reagents for the RAS signaling network.

Authors:  Regine M Schoenherr; Dongqing Huang; Uliana J Voytovich; Richard G Ivey; Jacob J Kennedy; Richard G Saul; Simona Colantonio; Rhonda R Roberts; Joseph G Knotts; Jan A Kaczmarczyk; Candice Perry; Stephen M Hewitt; William Bocik; Gordon R Whiteley; Tara Hiltke; Emily S Boja; Henry Rodriguez; Jeffrey R Whiteaker; Amanda G Paulovich
Journal:  Sci Data       Date:  2019-08-29       Impact factor: 6.444

Review 2.  If this is true, what does it imply? How end-user antibody validation facilitates insights into biology and disease.

Authors:  Karen S Sfanos; Srinivasan Yegnasubramanian; William G Nelson; Tamara L Lotan; Ibrahim Kulac; Jessica L Hicks; Qizhi Zheng; Charles J Bieberich; Michael C Haffner; Angelo M De Marzo
Journal:  Asian J Urol       Date:  2018-12-12

Review 3.  Anything You Can Do, I Can Do Better: Can Aptamers Replace Antibodies in Clinical Diagnostic Applications?

Authors:  Michelle Bauer; Mia Strom; David S Hammond; Sarah Shigdar
Journal:  Molecules       Date:  2019-11-30       Impact factor: 4.411

4.  Exploring the potential of BH3 mimetic therapy in squamous cell carcinoma of the head and neck.

Authors:  Rachel J Carter; Mateus Milani; Michael Butterworth; Ahoud Alotibi; Nicholas Harper; Govindaraju Yedida; Georgia Greaves; Aoula Al-Zebeeby; Andrea L Jorgensen; Andrew G Schache; Janet M Risk; Richard J Shaw; Terry M Jones; Joseph J Sacco; Adam Hurlstone; Gerald M Cohen; Shankar Varadarajan
Journal:  Cell Death Dis       Date:  2019-12-04       Impact factor: 8.469

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.